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Abstract
Background: Achieving good adherence to self-injected treatments for multiple sclerosis can be difficult. Injection
devices may help to overcome some of the injection-related barriers to adherence that can be experienced by
patients. We sought to assess short-term adherence to, and tolerability of, interferon (IFN) b-1a administered via
electronic autoinjection device in patients with relapsing-remitting multiple sclerosis (RRMS).
Methods: BRIDGE (RebiSmart to self-inject Rebif serum-free formulation in a multidose cartridge) was a 12-week,
multicentre, open-label, single-arm, observational, Phase IV study in which patients self-administered IFN b-1a
(titrated to 44 μg), subcutaneously (sc), three times weekly, via electronic autoinjection device. Patients were
assessed at baseline and 4-weekly intervals to Week 12 or early termination (ET) for: physical examinations; diary
card completion (baseline, Weeks 4, 8 only); neurological examinations (baseline, Week 12/ET only); MS Treatment
Concern Questionnaire (MSTCQ; Weeks 4, 8, 12 only); Convenience Questionnaire (Week 12 only); Hospital Anxiety
and Depression Scale (HADS); and Paced Auditory Serial Addition Task (PASAT; baseline only). Adherence was
defined as administration of ≥ 80% of scheduled injections, recorded by the autoinjection device.
Results: Overall, 88.2% (105/119; intent-to-treat population) of patients were adherent; 67.2% (80/119) administered
all scheduled injections. Medical reasons accounted for 35.6% (31/87) of missed injections, forgetfulness for 20.6%
(18/87). Adherence did not correlate with baseline Expanded Disability Status Scale (P = 0.821) or PASAT (P = 0.952)
scores, or pre-study therapy (P = 0.303). No significant changes (baseline-Week 12) in mean HADS depression (P =
0.482) or anxiety (P = 0.156) scores were observed. ‘Overall convenience’ was the most important reported benefit
of the autoinjection device. Device features associated with handling and ease of use were highly rated. Mean
MSTCQ scores for ‘flu-like’ symptoms (P = 0.022) and global side effects (P = 0.002) significantly improved from
Week 4-12. Mean MSTCQ scores for pain at injection site and injection pain increased from Week 4-12 (P < 0.001).
Adverse events were mild/moderate. No new safety signals were identified.
Conclusion: Convenience and ease of use of the autoinjection device may improve adherence and, therefore,
outcomes, in patients with RRMS receiving sc IFN b-1a.
Trial registration: EU Clinical Trials Register (EU-CTR; http://www.clinicaltrialsregister.eu): 2009-013333-24
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Background
Multiple sclerosis (MS) is a chronic, inflammatory,
degenerative, autoimmune disorder of the central ner-
vous system with onset usually in young adulthood [1].
Most patients (70-80%) present with the relapsing-
remitting form (RRMS), in which disability is accrued
through incomplete recovery from intermittent disease
relapses [1,2]. Approximately 50% of patients with
RRMS develop disease progression within 10 years of
disease onset [1,2].
There is currently no cure for MS. RRMS is treated
primarily with established disease-modifying drugs
(DMDs) aimed at reducing relapses. Current first-line
DMDs include interferon (IFN) b and glatiramer acetate
(GA), which are self-administered by subcutaneous (sc)
or intramuscular (im) injection. Treatment of MS is a
long-term commitment and outcomes may be influ-
enced by the level of adherence to DMDs. Premature
discontinuation and poor adherence have been asso-
ciated with increased risk of relapse and disability pro-
gression [3-7], and may be due to adverse events (AEs)
associated with the drug and route of administration
(injection-site reactions [ISRs]) [8], ‘flu-like’ symptoms
(FLS), perceived lack of efficacy, treatment fatigue, pain
at injection site, injection anxiety [3,9-11] or, simply,
forgetfulness. In some patients, forgetfulness and treat-
ment fatigue may be exacerbated by cognitive deficits,
depression and anxiety associated with MS [3,12].
Patients with MS may also experience impaired dexter-
ity, reducing the ability to self-inject [2].
Strategies are needed to assist patients and healthcare
providers to overcome and monitor adherence issues.
Autoinjection devices can improve the injection experi-
ence and increase patient satisfaction [13-16], which
could lead to improved adherence and treatment out-
comes [17]. An electronic, handheld, multidose, autoin-
jection device that incorporates a dosing history log has
been developed to improve the injection experience,
patient satisfaction and treatment adherence among
patients self-administering sc IFN b-1a. In a multicentre,
international user trial, this device was considered ‘very
suitable’ or ‘suitable’ for self-injection by 71.6% of
patients and 92.2% reported some degree of suitability
[14]. The objective of the study reported here was to
assess short-term treatment adherence and tolerability
in patients with RRMS who switched to sc IFN b-1a
administered using the autoinjection device, either from
other injectable DMD formulations or from sc IFN b-1a
administered using a different injection system.
Methods
BRIDGE (RebiSmart to self-inject Rebif serum-free for-
mulation in a multidose cartridge [EudraCT number:
2009-013333-24]) was a 12-week, multicentre, open-
label, single-arm, observational, Phase IV Italian study.
Patients were recruited from 17 treatment centres across
Italy between September 2009 and May 2010. The study
was performed in accordance with the Note for Gui-
dance on Good Clinical Practice (International Confer-
ence on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use, Topic
E6, 1996 and EU GCP Directive 2001/20/EC) and the
guiding principles of the Declaration of Helsinki, and
was approved by the Independent Ethics Committee/
Institutional Review Board at each participating
institution.
Patients
Patients aged 18-65 years were eligible to participate if
they had RRMS (according to revised 2005 McDonald
criteria [18]); were eligible for sc IFN b-1a treatment
(Rebif; Merck Serono S.A. — Geneva, Switzerland, a
branch of Merck Serono S.A., Coinsins, Switzerland, an
affiliate of Merck KGaA, Darmstadt, Germany), 44 μg
three times weekly [tiw]); were switching from another
injectable DMD or sc IFN b-1a using a different injec-
tion system; were able to self-inject using the autoinjec-
tion device (RebiSmart; Merck Serono S.A. — Geneva,
Switzerland); were willing and able to adhere to the pro-
tocol for the duration of the study; and had provided
written informed consent. Exclusion criteria included
any other disease that may more adequately explain
patient’s signs and symptoms; use of immunosuppres-
sive agents within 3 months of baseline; relapse within
30 days of baseline; pregnancy or breast-feeding, or refu-
sal by patients who were not post-menopausal or surgi-
cally sterile to use a highly effective method of
contraception throughout the study; elevated liver
enzyme levels; inadequate bone marrow reserve; moder-
ate-to-severe renal impairment; any visual impairment
preventing self-injection with the autoinjection device;
hypersensitivity to IFN or to any excipients; contraindi-
cations to ibuprofen; participation in any other investi-
gational trial within 30 days of baseline; and any other
significant disease that, in the opinion of the recruiting
physician, would contraindicate participation in the trial.
Study design
During the screening period, demographic data, medical
history (including history of MS), blood and urine sam-
ples, and details of concomitant medications/procedures,
medical conditions (safety assessment) and contraceptive
methods were collected. Patients underwent physical
and neurological examinations, a serum pregnancy test
(where appropriate), and review of inclusion/exclusion
criteria. Patients could withdraw from the study at any
Lugaresi et al. BMC Neurology 2012, 12:7
http://www.biomedcentral.com/1471-2377/12/7
Page 2 of 10
time. Upon withdrawal, all assessments required at the
early termination (ET) visit were completed at the ear-
liest time possible.
Patients underwent five study assessments over a 12-
week period (Additional file 1: Figure S1): baseline (Visit
1/Study Day 1, conducted within 14 days of screening
completion), Visit 2 (Week 2; telephone call), Visit 3
(Week 4), Visit 4 (Week 8) and Visit 5 (Week 12/ET).
Treatment began at Visit 1 following completion of all
baseline evaluations and patient training in the use of
the autoinjection device.
Interventions
Patients were provided with pre-filled cartridges, each
containing three doses (44 μg/0.5 mL) of the serum-free
(without foetal bovine or human serum albumin excipi-
ents) formulation of IFN b-1a, for self-injection sc tiw,
using the electronic autoinjection device. IFN b-1a dose
was titrated up over a 4-week period (8.8 μg/0.1 mL for
the first 2 weeks, 22 μg/0.25 mL during Weeks 3 and 4,
followed by the full dose of 44 μg/0.5 mL from Week 5
to 12). The study drug was to be administered at
approximately the same time each day, on the same 3
days of the week, with a minimum of 48 h between
injections. Patients were advised to rotate injection sites
and to avoid injecting into inflamed areas. Dose reduc-
tion was not permitted and resulted in withdrawal of
the patient from the study. Ibuprofen (400 mg prior to
each injection and additional ibuprofen as necessary to
maximum of 1200 mg/day) for the treatment of FLS
was mandatory for the first 4 weeks of the study, after
which ibuprofen was to be taken as required, according
to the investigator’s medical practice dosing schedule.
Assessments
The assessment schedule is summarized in Additional
file 1: Figure S1. Concomitant medications and AEs
were recorded at all study visits. Patients underwent a
physical examination at baseline and Weeks 4, 8 and
12/ET. A neurological examination, including Expanded
Disability Status Scale (EDSS) score, was performed at
baseline and Week 12/ET. Cognitive function was
assessed at baseline using the Paced Auditory Serial
Addition Task (PASAT), a serial addition task used to
assess information processing speed, working memory
and sustained attention on a scale of 0-60 (higher score
indicating better cognitive function). Clinically signifi-
cant depression and anxiety were assessed using the
Hospital Anxiety and Depression Scale (HADS) at base-
line and Weeks 4, 8 and 12/ET. Patients completed the
MS Treatment Concern Questionnaire (MSTCQ) at
Weeks 4, 8 and 12 to report FLS, ISRs and global side
effects (GSEs), as well as the most important benefit of
the autoinjection device from a list of five options, pain
over the past 4 weeks (visual analogue scale [VAS]) on a
scale of 0 (no pain) to 100 (worst possible pain), and
pain upon injection during past 4 weeks on a scale of 1
(no pain) to 5 (horrible, excruciating pain). Reasons for
missed injections were recorded using patient diary
cards at baseline, Week 4 and Week 8. Patients also
completed a Convenience Questionnaire (scale of 0-5,
where lower scores indicate greater convenience) at
Week 12 to provide an overall evaluation of the autoin-
jection device.
Study endpoints
The primary endpoint was the proportion of patients at
Week 12 who were adherent to treatment, defined as
having administered ≥ 80% of scheduled injections over
the course of the study, as logged by the autoinjection
device. Patients who administered < 80% of scheduled
injections were considered non-adherent. Adherence
was calculated as 100 × (number of injections the
patient administered)/(expected number of injections)
over the 12-week study period. The 80% cut-off was
chosen in accordance with previous studies on adher-
ence using medication possession ratio (MPR) [19-22].
Secondary endpoints included changes in MSTCQ
scores for side effects, device benefits and injection pain
at Weeks 4, 8 and 12; change from baseline in HADS
scores at Weeks 4, 8 and 12; overall evaluation of device
convenience at Week 12; correlation of adherence at
Week 12 with baseline PASAT score; frequency and rea-
sons for premature discontinuation; and reasons for
missed injections. Safety endpoints included treatment-
emergent adverse events (TEAEs), including serious
adverse events (SAEs), abnormal laboratory parameters
and physical examination findings, and any concomitant
medications and procedures.
Analysis populations
The intent-to-treat (ITT) population was defined as all
enrolled patients who had been assigned the autoinjec-
tion device. The safety population included all patients
in the ITT population who had received at least one
dose of the study drug.
Statistical analyses
No hypothesis testing was conducted. A total of 120
patients were required to provide a 95% confidence
interval (CI) equal to the sample proportion with 7%
precision, based on the hypothesis that 80% of patients
using the autoinjection device for 12 weeks would
administer 80% of scheduled injections.
For the primary endpoint, the proportion of patients
adherent to treatment in the ITT population and corre-
sponding 95% CI was calculated. For the secondary end-
points, changes in adherence and VAS score over time
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were analysed using repeated-measures analysis of var-
iance (ANOVA). Changes in ordinal scores over time
(MSTCQ side-effect subscales, HADS, ratings) were
analysed using the Friedman non-parametric test.
Descriptive statistics were reported for device benefits,
results of the Convenience Questionnaire, reasons for
missed injections and reasons for withdrawal from the
study. A Wilcoxon test was used to analyse change from
baseline in EDSS scores. The predictive value of PASAT
to assess non-adherence was analysed using the Student
t-test and linear regression, or Spearman’s r test as
appropriate.
Logistic regression analyses using a forward stepwise
method were performed to identify predictors of adher-
ence, incorporating age, sex, disease duration, previous
treatment, relapse frequency, and EDSS, PASAT and
HADS scores. A post hoc analysis using Pearson’s corre-
lation was performed to investigate the relationship
between HADS scores and FLS, ISRs and GSEs. Further
post hoc analyses were performed to examine adherence
in patients who had completed the study, creating the
completers’ population. Adherence in the completers’
population was calculated as 100 × (number of adminis-
tered injections)/(expected number of planned injections
before withdrawal). Application of this analysis to the
ITT population was also performed to assess adherence,
with adjustments for missed injections due to withdra-
wals. Statistical significance was set at a level of 5%. Sta-
tistical analyses were performed using SPSS for
Windows, version 18 (Chicago, IL, USA, 2002).
Results
Patients
A total of 120 patients were recruited: 119 were
included in the ITT population, 10 prematurely discon-
tinued treatment and 109 completed the study (comple-
ters’ population) (Figure 1). One patient withdrew from
the study prior to administration of the first dose of
study drug (Visit 1) and was excluded from the ITT
population.
Patients were predominantly women (75.6% [90/119]),
with a mean (standard deviation [SD]) age of 37.9 (9.68)
years, a mean (SD) MS duration of 5.8 (5.31) years and
a mean (SD) EDSS score of 2.1 (1.2; median: 2, range 0-
6) (Additional file 1: Table S1). Prior to the study, most
patients were receiving im IFN b-1a (63.0% [75/119]);
only 2.5% (3/119) switched from sc IFN b-1a adminis-
tered using a different injection system (Table 1).
Treatment adherence
Overall, 88.2% (105/119) of patients administered ≥ 80%
of scheduled injections over the 12-week study period
(ITT population; Figure 2). Treatment adherence was
similarly high in women (87.8% [79/90]) and men
(89.7% [26/29]). No significant correlation between
adherence and baseline EDSS score (P = 0.821) or pre-
study DMD (P = 0.303) was observed. Overall, the pro-
portions of patients adherent to treatment stratified by
pre-study DMD were 84.0% (63/75; im IFN b-1a), 93.3%
(14/15; GA), 96.2% (25/26; sc IFN b-1b) and 100% (3/3;
sc IFN b-1a). The proportion of patients who were
adherent to treatment (i.e. administered ≥ 80% of sched-
uled injections) decreased significantly over time (P <
0.001; repeated measures ANOVA) from 99.2% (118/
119) at Week 4 to 95.6% (114/119) at Week 8 and
81.5% (97/119) at Week 12. Sixty-seven percent of
patients (80/119) administered all (100%) scheduled
injections over the 12-week study; however, this propor-
tion decreased significantly over time (P < 0.01) from
99.2% (118/119) at Week 4 to 95.0% (113/119) at Week
8 and to 67.2% (80/119) at Week 12.
In the completers’ population, 96.3% (105/109) of
patients were adherent to treatment, although a signifi-
cant decrease in adherence was observed over the
course of the study (P < 0.001), from 100% through to
Week 4, to 99.1% (108/109) in Weeks 5-8, and to 89.0%
(97/109) in Weeks 9-12. When stratified by pre-study
DMD, 94.0% (63/67; im IFN b-1a), 100% (14/14; GA),
100% (25/25; sc IFN b-1b) and 100% (3/3; sc IFN b-1a)
of patients in the completers’ population were adherent
to treatment. All scheduled injections were administered
by 73.4% (80/109) of patients over the 12-week study
period. Post hoc analysis of adherence in the ITT popu-
lation, based on expected number of planned injections
prior to withdrawal, revealed that 91.6% (109/119) were
adherent to treatment throughout study duration.
Mean (SD) baseline PASAT score was similar in
patients who were adherent (42.67 [10.9], n = 102) and
those who were not adherent (42.86 [13.0], n = 14) to
Assessed for
eligibility (n=120)
Completers’ 
population (n=109)
Excluded (n=1)
• Declined to participate (n=1)
Allocated to intervention (ITT population: n=119)
• Received allocated intervention (n=119)
Discontinued intervention (n=10)
• Adverse event (n=7)
 • Fatigue and irritability (n=1)
 • Lymphopoenia (n=1)
 • Fatigue and ISR (n=1)
 • Liver enzyme increase (n=2)
 • Pregnancy (n=2)
• Patient consent withdrawal (n=3)
 • Protocol deviations (n=1)
 • Request for lower dose (n=1)
 • No compliance with device (n=1)
Figure 1 Patient disposition. ISR, injection-site reaction; ITT, intent-
to-treat.
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treatment. No significant correlation between adherence
and baseline PASAT score was observed (Spearman’s
correlation: r = -0.011; P = 0.909). No significant pre-
dictors of treatment adherence or tolerability were iden-
tified using logistic regression analysis for each baseline
variable (data not shown). Mean HADS depression or
anxiety scores did not differ significantly from baseline
at Weeks 4, 8 and 12 (P = 0.482 and P = 0.156,
respectively).
Overall, 35.6% of missed injections (31/87) were due
to medical reasons (patients experienced AEs that pre-
cluded injection), 20.7% (18/87) due to forgetfulness and
27.6% (24/87) due to ‘other reasons’. Pain at the injec-
tion site and ‘problems using the autoinjection device’/
’device unusable’ accounted for 3.4% (3/87) and 6.9% (6/
87) of missed injections, respectively. At Weeks 4 and 8,
most injections were missed due to medical reasons
(42.3% [11/26] and 40.1% [11/27], respectively), while at
Week 12 most were due to ‘other’ reasons (42.4% [14/
33]) and medical reasons accounted for 27.3% [9/33] of
missed injections.
Evaluation of the injection process
Mean MSTCQ scores improved significantly from Week
4 to 12 for the FLS (P = 0.022) and GSE (P = 0.002)
domains, but not for ISR (Table 2). However, a post hoc
analysis revealed a significant positive correlation
between FLS at Week 8 and HADS scores at baseline
and Weeks 4, 8 and 12 for anxiety (Pearson’s correla-
tion: r = 0.203-0.298; P < 0.05) and depression (Pear-
son’s correlation: r = 0.212-0.330; P < 0.05). A positive
correlation was also seen between GSE at Weeks 4, 8
and 12 and HADS scores for anxiety and depression at
all study visits (P ≤ 0.001; Pearson’s correlation: r =
0.301-0.495 at Week 4, 0.340-0.519 at Week 8 and
0.322-0.490 at Week 12).
Pain at injection site (mean [SD] VAS score) signifi-
cantly increased over time (P < 0.001; repeated measures
ANOVA) from 15.7 (18.82; n = 116) at Week 4 to 28.4
Table 1 Baseline characteristics according to pre-study DMD treatment (intent-to-treat population; n = 119)
Number (%) of
patients
Age,
years
Duration of MS,
years
EDSS
score*
PASAT
score†
HADS Anxiety
score‡
HADS Depression
score‡
Pre-study
DMD
Median (range); 95% confidence interval
im IFN b-1a 75 (63.0) 39 5 2¶ 42.5 7 5
(19-58) (0-22) (0-5.5) (5-60) (0-20) (0-20)
35.6, 39.9 4.9, 7.3 1.9, 2.4 40.0, 45.3 6.9, 9.2 4.9, 7.0
IFN b-1b 26 (21.8) 37 3.5 1.5 48 7 3.5
(20-52) (0-22) (0-6) (24-59) (0-13) (0-15)
34.1, 42.4 3.1, 8.6 1.3, 2.4 42.6, 50.8 5.0, 7.8 3.5, 7.1
Glatiramer
acetate
15 (12.6) 41 4 1.5 35 7 3
(18-55) (1-8) (0-4.5) (18-52) (0-14) (0-12)
31.7, 44.5 2.7, 5.3 1.3, 2.9 30.5, 41.9 3.8, 9.0 2.3, 7.0
sc IFN b-1a 3 (2.5) 35 6 3 46 4 6
(22-43) (6-11) (2-4) (25-51) (4-10) (2-6)
7.0, 59.6 0.5, 14.8 0.5, 5.5 6.4, 74.9 -2.6, 14.6 -1.1, 10.4
*Range: 0 (no disability) to 10 (severe disability resulting in death)
†Range: 0 to 60 (higher scores indicate better cognitive function)
‡Range: 0 to 21 (higher scores indicate more severe symptoms)
¶n = 72
DMD disease-modifying drug, EDSS Expanded Disability Status Scale, HADS Hospital Anxiety and Depression Scale, IFN interferon, im intramuscular, MS multiple
sclerosis, PASAT Paced Auditory Serial Addition Task, sc subcutaneous
100
80
Pa
tie
nt
s 
(%
)*
60
40
20
0
<40 40–59 60–69
Adherence (%)
70–79 80–89 ≥90
n=2 n=3 n=3 n=6
n=7
n=98
1.7 2.5 2.5 5
5.9
82.4
88.2
Figure 2 Patient adherence at Week 12 in the intent-to-treat
population (n = 119). *Percentages may not add up to 100 due to
rounding.
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(27.37; n = 109) at Week 8 and to 31.2 (27.57; n = 107)
at Week 12. Pain upon injection (mean [SD] MSTCQ
score) also increased significantly (P < 0.001) from 2.1
(0.99) at Week 4 to 2.55 (1.05) at Week 8 and to 2.49
(1.03) at Week 12. The mean (SD) number of ibuprofen
tablets taken decreased from 23.4 (8.60) at Week 4 to
18.7 (11.03) at Week 8 and 13.9 (11.77) at Week 12.
There was no significant correlation, however, between
the number of ibuprofen tablets taken and VAS score
for pain at injection site at Weeks 4, 8 and 12 (p >
0.398, respectively).
Overall device evaluation
Based on patient experience, overall convenience was
consistently reported as the most important benefit of
the electronic autoinjection device at Weeks 4 (38.5%;
40/104), 8 (42.3%; 41/97) and 12 (44.6%; 41/92; Addi-
tional File 1: Figure S2). The second most important
benefit of the autoinjection device was reported to be
less injection pain (24.0%; 25/104) at Week 4 and fewer
FLS at Weeks 8 (19.6%; 19/97) and 12 (23.9%; 22/92).
When stratified according to pre-study DMD, less injec-
tion pain was reported as the most important benefit by
patients receiving pre-study sc IFN b-1b (40.0%; 10/25)
and fewer FLS by patients receiving sc IFN b-1a (66.7%;
2/3) at Week 4. Convenience and fewer FLS were each
reported as the most important benefit by 50.0% (1/2
and 1/2, respectively) of the patients receiving sc IFN b-
1a at Week 12. Patients receiving pre-study GA reported
fewer ISRs as the most important benefit at Week 12
(50.0%; 4/8) and as the second most important benefit
at Week 8 (36.4%; 4/11). Patients receiving pre-study im
IFN b-1a consistently reported convenience as the most
important benefit, and fewer FLS as the second most
important benefit, at Weeks 4, 8 and 12.
At Week 12, patients rated the autoinjection device as
highly convenient to use, with an overall median evaluation
score of 1.4 (range 1.2-1.9). Most patients thought it was
‘very easy’ to change the multidose cartridge (74.1% [80/
108]); to inject using the device (62.6% [67/107]); to store
(61.7% [66/107]), transport (57.5% [61/106]) and hold
(56.1% [60/107]) the device; and to both attach (55.1% [59/
107]) and detach (55.1% [59/107]) the needle. Less than
half of patients thought it was ‘very easy’ to change the
comfort settings (47.1% [48/102]) and the batteries (35.1%
[33/94]), and that the device was ‘very’ attractively designed
(43.8% [46/105]) and silent (43.5% [47/108]).
Safety
A total of 432 AEs were reported; 96.8% (418/432) were
mild or moderate in severity, 60.6% (262/432) were con-
sidered to be treatment related, 1.6% (7/432) resulted in
temporary interruption of treatment and 1.6% (7/432) in
discontinued use of the study drug. Of the patients who
withdrew from the study because of AEs, one did so
due to an injection-related AE (injection-site pain),
which presented in association with fatigue. Five patients
withdrew from the study for non-device-related reasons
(dose adjustment [1 patient], pregnancy [2 patients] and
DMD-related toxicity [2 patients]). The most frequent
AEs were FLS, headache and ISRs (Table 3). One (0.2%)
SAE was reported, which required hospitalization of the
patient and was considered to be related to the study
drug (elevated liver enzymes).
Discussion
The objective of this study was to assess short-term
adherence and tolerability of sc IFN b-1a, self-
Table 2 Summary of changes in MSTCQ scores from
Week 4 to 12 in the intent-to-treat population (n = 119)
Time point ISR* FLS* GSE†
Week 4 (n = 115)
Mean (SD) 13.2 (4.02) 13.4 (4.56) 6.8 (3.16)
Median (range) 13 (4-19) 13 (6-20) 6 (3-15)
Week 8 (n = 109)
Mean (SD) 13.4 (3.64) 12.9 (4.10) 7.5 (3.16)
Median (range) 13.5 (6-20) 12 (5-20) 8 (3-15)
Week 12 (n = 104)
Mean (SD) 13.1 (3.39) 12.2 (4.30) 7.6 (3.05)
Median (range) 13 (6-20) 11 (5-20) 8 (3-15)
p-value‡ 0.902 0.022 0.002
*Range: 1 (mild) to 20 (severe)
†Range: 1 (poor treatment satisfaction) to 15 (excellent treatment satisfaction)
‡Repeated measures analysis of variance
FLS ’flu-like’ symptoms, GSE global side effects, ISR injection-site reactions;
MSTCQ Multiple Sclerosis Treatment Concern Questionnaire, SD standard
deviation
Table 3 Total treatment-emergent adverse events (intent-
to-treat population, n = 119)
Adverse event n (%)
’Flu-like’ symptoms 170 (39.4)
Headache 84 (19.4)
Injection-site reaction 46 (10.6)
Gastrointestinal abnormalities 25 (5.8)
Pain 20 (4.6)
Anxiety 13 (3.0)
Infections 10 (2.3)
Hypersensitivity reaction 7 (1.6)
Cytopenia 7 (1.6)
Hepatic disorders 7 (1.6)
Vertigo 6 (1.4)
Upper respiratory tract infection 5 (1.1)
Tachycardia 4 (0.9)
Dysmenorrhoea 3 (0.7)
Other 25 (5.8)
Total 432 (100)
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administered using an electronic autoinjection device, in
patients with RRMS who had switched from another
injectable DMD or a different injection system for sc
IFN b-1a. Over 85% of patients were adherent to treat-
ment over the 12-week course of the study, as recorded
by the device dosing log. When adherence was adjusted
to account for missed injections by patients who with-
drew from the study for non-device-related reasons,
adherence was 92%. The high adherence rates reported
in this study are consistent with findings of a previous
study, in which most patients found the same autoinjec-
tion device to be suitable or very suitable for self-injec-
tion of sc IFN b-1a [14]. Notably, this earlier study did
not assess adherence, as recorded objectively by the
device dosing log.
Adherence did not correlate with baseline cognitive
function (measured using the PASAT) and no predictors
of adherence were identified. The absence of identified
predictors may reflect certain characteristics of the
study population: most patients were under 40 years of
age with low levels of disability and very good cognitive
function. Overall, the safety profile of IFN b-1a serum-
free formulation in the current study was consistent
with previous observations with the original IFN b-1a
formulation [23-25].
Adherence rates were very high at the start of the
study but decreased as the study progressed. This may
have been due to patients experiencing IFN-specific AEs
once the drug was administered at full dose, particularly
FLS, one of the most common AEs associated with IFN
therapy. However, the most common reason for missing
injections changed from medical reasons at Weeks 4
and 8 to ‘other’ reasons at Week 12. Forgetfulness, one
of the most common reasons for missed injections [5],
was responsible for 21% of missed injections overall and
may be particularly problematic in patients with
impaired cognitive function due to MS. Baseline cogni-
tive function was very good in the majority of patients
and did not predict adherence in this study. However,
the PASAT test, which was used to assess cognitive
function in this study, measures attention and working
memory rather than the long-term memory skills that
are required for processes such as remembering to per-
form regular injections, so the lack of association
between PASAT score and adherence may not be sur-
prising. Therefore, no conclusions could be drawn
regarding the relation between cognitive function and
adherence using the autoinjection device. In addition, to
what extent different cognitive functions influence
adherence in general is not fully understood. Further-
more, it should be considered that patients may prefer
to give ‘forgetfulness’ as the reason for missing one or
more injections rather than other reasons which may be
considered more problematic by their neurologist, such
as treatment fatigue.
No significant baseline predictors of adherence were
identified; however, depression may have influenced
treatment outcome. Depression, a common symptom of
MS, may reduce motivation, which may in turn reduce
adherence. Indeed, depression has previously been
reported to be a cause of treatment discontinuation [8].
No significant correlation between depression and
adherence was observed in this study, however, and a
longer study period would be required to explore the
relation between depression and adherence to MS ther-
apy. The positive correlation between baseline HADS
scores and reported FLS and GSE over the course of the
study suggests that depression and anxiety may increase
the extent to which patients are aware of side effects
and also their perception of the magnitude of such
events.
The high adherence rates in this 12-week study are
encouraging, particularly as the use of an autoinjection
device to collect adherence data likely provides a more
reliable indication of adherence to treatment than other
measures of adherence such as MPR or retrospective
self-reporting by patients used in other studies [3,26,27].
The high level of adherence may indicate that most
patients found the device convenient and easy to use.
Convenience, less injection pain and fewer FLS were
rated by patients as the most important benefits of the
autoinjection device. Overall, convenience was reported
as the main benefit throughout the study, consistent
with previous studies of this device [14,28]. Notably,
device features associated with handling and ease of use
were rated highly. The majority of patients found it
‘very easy’ to change the multidose cartridge and needle,
hold the device and perform the injection. Simplification
of the injection process, for example through the use of
an autoinjection device that only needs to be loaded
once a week, may encourage patients to perform injec-
tions and alleviate treatment fatigue. Such features may
also be particularly beneficial to patients who have
impaired dexterity due to MS [2], increasing treatment
satisfaction and independence. The majority of patients
also thought the device was ‘very easy’ to transport,
which may assist patients with MS to adhere to treat-
ment while travelling and on holiday.
Patients considered ‘less injection pain’ to be the sec-
ond most important benefit of the autoinjection device
at Week 4 and the third most important benefit at
Weeks 8 and 12. As the study progressed, patients
reported an increase in both pain at the injection site
and pain upon injection. Repeated injections may cause
progressive damage (e.g. nodules, bruises) to sc tissue,
thus increasing injection pain. These side effects may be
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http://www.biomedcentral.com/1471-2377/12/7
Page 7 of 10
particularly problematic to patients who are unaccus-
tomed to sc injections, such as patients who switched
from im IFN b-1a, which comprised 63% of our study
population. As data regarding injection-related pain with
prior treatment were not collected, it is not known how
injection pain during the study compared with previous
injection experience.
All injectable DMDs are associated with ISRs; how-
ever, symptoms and reaction severity vary depending on
the drug and the route of administration. ISRs are more
commonly associated with sc rather than im injections
[8]. As 63% of patients in this study switched from im
to sc injections, an increase in ISRs in either this subset
of patients or the total patient population would not be
unexpected. Mean ISR score, however, did not change
from baseline over the course of the study, suggesting
that patients did not note an increase in ISRs when
switching to sc injection. Despite this, ‘fewer ISRs’ was
reported as the most important benefit of the device by
7% of patients in this subgroup at Week 8. ‘Fewer ISRs’
was rated as the most important benefit of the device at
Week 12, and second most important benefit at Week
8, by patients previously receiving sc GA therapy. ISRs
are the most common side effect associated with GA
injections [29], therefore the reported reduction may
have been due to a switch in both DMD and device.
Overall, patients reported a decrease in FLS over the
course of the study despite a concurrent reduction in
ibuprofen usage, and ‘fewer FLS’ was reported as the
second most important benefit at Weeks 8 and 12.
However, it should be noted that the autoinjection
device is unlikely to be implicated in the observed
reduction in FLS. As discussed previously, pre-study
DMD therapy would have likely influenced AEs experi-
enced during the study. FLS are one of the most com-
mon AEs associated with IFN b therapy, which was
being received by 87% of patients prior to the study. No
change in FLS during the study would have been
expected in patients receiving pre-study sc IFN b. FLS
may have worsened in some patients previously receiv-
ing im IFN b-1a owing to increased IFN dose and injec-
tion frequency [30]; however, increased injection
frequency may favour tachyphylaxis, therefore reducing
the presence and severity of FLS (authors’ personal
observations) [31]. Indeed, fewer FLS were consistently
reported as the second most important benefit of the
autoinjection device by patients receiving pre-study im
IFN b-1a at Weeks 4, 8 and 12. Patients switching from
GA would have been unaccustomed to FLS, which are
particularly prevalent in the first few weeks of treatment
with IFN b [8,32] and occur most frequently for the
first 6 months. In addition to FLS, global side effects
improved over the course of the trial. As ibuprofen
usage was mandatory for the first 4 weeks of the study,
whether reduction in ibuprofen usage was a result of
reduced AEs is unknown. Recent reports on side effects
related to ibuprofen use, however, may suggest that its
usage should be adjusted according to the presence and
severity of side effects [33].
Limitations of the study should be considered when
interpreting the study findings. At 12 weeks, the study
was only able to assess short-term adherence; however,
we are exploring the possibility of assessing safety, toler-
ability and treatment adherence/persistence after longer-
term follow-up in this patient population. Absence of
data on adherence to previous medication and pre-study
or baseline injection pain precludes inferences on the
benefits of switching to the autoinjection device with
respect to adherence and injection pain. In addition,
patient perception and reporting of pain is subjective.
Pre-study DMDs were not equally represented among
patients, with the majority switching from im IFN b-1a;
this imbalance limited the conclusions that could be
drawn regarding the influence of previous treatment on
subsequent outcomes. For example, pre-study DMD
may have influenced AEs, patient perception of injec-
tion-related AEs and, therefore, opinion of the autoin-
jection device. Finally, there was no control group in
this observational study, so we were not able to discri-
minate between the effects of the new device and those
of changing treatment in patients who had switched to
sc IFN b-1a from a different DMD at study entry. How-
ever, a previous international study of this new device
recruited only patients already being treated with sc IFN
b-1a [14]; therefore, the effects of changing device have
only previously been reported for some of the para-
meters investigated in the current study.
Conclusions
In conclusion, the convenience and ease of use of an
electronic autoinjection device may increase adherence
in patients with RRMS, allowing patients to receive the
full benefits of DMD therapy.
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